

**SENATE**  
**STATE OF MINNESOTA**  
**NINETIETH SESSION**

**S.F. No. 1902**

(SENATE AUTHORS: KLEIN, Koran and Abeler)

DATE  
03/08/2017

D-PG  
1181

Introduction and first reading  
Referred to Health and Human Services Finance and Policy

OFFICIAL STATUS

1.1 A bill for an act  
1.2 relating to health care; permitting drugs used for weight loss to be covered under  
1.3 the medical assistance program; amending Minnesota Statutes 2016, section  
1.4 256B.0625, subdivision 13d.

1.5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.6 Section 1. Minnesota Statutes 2016, section 256B.0625, subdivision 13d, is amended to  
1.7 read:

1.8 Subd. 13d. **Drug formulary.** (a) The commissioner shall establish a drug formulary. Its  
1.9 establishment and publication shall not be subject to the requirements of the Administrative  
1.10 Procedure Act, but the Formulary Committee shall review and comment on the formulary  
1.11 contents.

1.12 (b) The formulary shall not include:

1.13 (1) drugs, active pharmaceutical ingredients, or products for which there is no federal  
1.14 funding;

1.15 (2) over-the-counter drugs, except as provided in subdivision 13;

1.16 ~~(3) drugs or active pharmaceutical ingredients used for weight loss, except that medically~~  
1.17 ~~necessary lipase inhibitors may be covered for a recipient with type II diabetes;~~

1.18 ~~(4)~~ (3) drugs or active pharmaceutical ingredients when used for the treatment of  
1.19 impotence or erectile dysfunction;

1.20 ~~(5)~~ (4) drugs or active pharmaceutical ingredients for which medical value has not been  
1.21 established;

2.1 ~~(6)~~ (5) drugs from manufacturers who have not signed a rebate agreement with the  
2.2 Department of Health and Human Services pursuant to section 1927 of title XIX of the  
2.3 Social Security Act; and

2.4 ~~(7)~~ (6) medical cannabis as defined in section 152.22, subdivision 6.

2.5 (c) If a single-source drug used by at least two percent of the fee-for-service medical  
2.6 assistance recipients is removed from the formulary due to the failure of the manufacturer  
2.7 to sign a rebate agreement with the Department of Health and Human Services, the  
2.8 commissioner shall notify prescribing practitioners within 30 days of receiving notification  
2.9 from the Centers for Medicare and Medicaid Services (CMS) that a rebate agreement was  
2.10 not signed.